Imeth

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Imeth

What is Imeth? Defining the Medicine

Property Description
Active Ingredient Methotrexate (MTX)
Forms Oral Tablet, Sterile Solution for Injection
Pharmacological Class Antimetabolite, Antifolate, Immunosuppressant
Common Use Managing chronic inflammatory and autoimmune conditions
Origin Synthetic compound, derivative of Folic Acid

Imeth is a brand name for a potent, prescription-only medication containing the active pharmaceutical ingredient Methotrexate (MTX), a substance chemically related to folic acid (Vitamin B9). It is fundamentally classified as an antimetabolite and is chemically recognized as an antifolate agent because it interferes with essential cellular processes that rely on folates. The product is manufactured as a single-active-ingredient formulation, available either as tablets for oral use or as a sterile solution for injection for parenteral administration.

Imeth's Pharmacological Class and General Purpose

Methotrexate belongs to the high-level pharmacological class of antimetabolites and is also broadly categorized as a powerful immunosuppressant and cytotoxic agent. This dual classification defines its overall therapeutic utility: its primary action is to disrupt the production of genetic material, which slows the replication of specific, rapidly dividing cells. Concurrently, it modulates the overactivity of the immune system. Consequently, the medicine is used for long-term management by addressing the underlying cause of immune-mediated inflammation and uncontrolled cell proliferation.

Guiding Principles of Imeth Use

The effects of Imeth are dictated by the dose and context of administration. The drug is capable of delivering low, sustained doses to achieve primarily immunosuppressive effects, or higher, pulsed doses to utilize its stronger cytotoxic capacity to inhibit rapid cell proliferation. This strategic differentiation in application—which is a key feature of the Methotrexate molecule—guides its entire medical application, ensuring its function is tailored to the specific therapeutic goal. All detailed usage protocols, specific schedules, and safety information are strictly governed by prescriptive guidelines.

Regulatory References

  1. Methotrexate - StatPearls - NCBI Bookshelf - NIH

What side effects are possible with Imeth?

Possible Side Effects and Safety Information

The safety profile of Imeth, which contains methotrexate, is established through official regulatory documents that classify potential adverse reactions based on their observed frequency and the physiological systems affected. Reactions are grouped by frequency, such as Very Common (1/10) and Common (1/100 to < 1/10).


Adverse Reaction Classifications

Very Common reactions typically involve the Gastrointestinal System, including stomatitis (inflammation of the mouth), nausea, and vomiting, alongside elevations in liver function tests. Common effects extend to the skin (erythematous rashes, alopecia), nervous system (headache, dizziness), and blood system (leukopenia).

Serious Adverse Reactions and Safety Constraints

The medicine is associated with documented Serious Adverse Reactions, including myelosuppression (severe bone marrow suppression), pneumonitis (lung inflammation), and significant hepatotoxicity (liver damage). These effects often require close observation. The official labeling specifies safety restrictions related to duration and pre-existing conditions:

  • Time-related Patterns: Acute pneumonitis may be observed more frequently at the initiation of treatment, while the risk of chronic liver damage is associated with long-term exposure.
  • Organ Impairment: Imeth is officially restricted for use in individuals with severe renal impairment and significant hepatic impairment due to increased toxicity risk.
  • Population Notes: It is contraindicated in pregnancy for non-neoplastic use due to the risk of harm to the fetus, and older adults require specialized monitoring.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Imeth (Methotrexate) overdose is defined by its acute, multi-system cytotoxic effects, which can be severe and life-threatening. The most critical overdose scenario involves accidental daily dosing instead of the prescribed weekly schedule, which requires immediate intervention.

Overdose manifestations are primarily characterized by the resultant damage to rapidly dividing cells, leading to severe hematologic suppression, including myelosuppression and pancytopenia. Gastrointestinal toxicity is common, presenting as severe mucositis and ulcerative stomatitis, with a risk of progression to hemorrhagic enteritis and fatal intestinal perforation.

Acute kidney injury (AKI) is a significant concern, as impaired renal function severely delays drug clearance, leading to prolonged exposure and escalating systemic toxicity. Patients with pre-existing impaired renal function or third-space fluid accumulation face a heightened risk of fatal complications.

Immediate medical attention must be sought upon any suspicion of an overdose or accidental dosing error. Regulatory labels mandate the prompt administration of the specific antidote, Leucovorin (folinic acid), to counteract toxicity. Supportive measures, which are essential for management, include forced hydration and urinary alkalinisation, guided by continuous monitoring of serum methotrexate concentrations, complete blood counts, and renal function.

Therapeutic Uses of Imeth

What Imeth Treats: Main Uses and Benefits

Imeth is commonly used across conditions characterized by periods of heightened symptoms, or involving episodic and fluctuating manifestations. It is relevant when symptoms become more noticeable and supportive management is appropriate. The class of medication relevant to Imeth is often applied in managing conditions that involve fluctuations, such as those that cycle between periods of less activity and flare-ups. The relevant therapeutic domains include symptoms related to inflammatory or irritative states and symptoms related to systemic imbalance.

The medication may provide support that helps ease the overall symptom burden during difficult episodes. It assists with maintaining a sense of stability when symptoms are more noticeable. Imeth may assist with functional stability when symptoms cluster into patterns and create noticeable functional strain or interfere with routine activities. It is relevant in clinical settings where short-term supportive relief is needed.

Quick Fact: Supportive Management for Episodic Symptoms

Eligibility and Restrictions for Use

Eligibility Profile: Who Can and Cannot Use Imatinib?

This section outlines the official eligibility and non-eligibility information as documented in government regulatory labeling (e.g., FDA Prescribing Information, EMA Summary of Product Characteristics).

Classification Population/Condition Restriction Detail (Based on Regulatory Status)
Contraindicated Hypersensitivity Must not be used in patients with documented hypersensitivity to Imatinib or any excipients.
Use Restricted Pregnancy Not recommended; should be avoided unless the benefit clearly outweighs the potential risk. Patient must be informed of potential fetal harm.
Use Restricted Lactation (Breastfeeding) Not recommended; women should not breastfeed during treatment and for a specified period (e.g., one month) after the last dose.
Conditional Use Hepatic Impairment Requires caution and close monitoring; initial dosage reduction is mandatory for severe impairment.
Conditional Use Severe Renal Impairment Use with caution; insufficient regulatory data to recommend a standard dosage.
Age Restriction Children Younger than 1 year Use is not established for most approved indications (e.g., CML, ALL).
Conditional Use Cardiac Risk Factors Caution advised for patients with existing cardiac disease or risk factors; requires monitoring for left ventricular dysfunction or congestive heart failure.

This eligibility structure is defined by official regulatory bodies, establishing a basis for absolute exclusion (hypersensitivity) and identifying specific conditions or life stages that require special caution, monitoring, or restricted use.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents classify interactions with Imeth (methotrexate) based on effects on drug clearance and additive toxicity. The following combinations and effects are officially documented in government-approved prescribing information.

Contraindicated and High-Risk Combinations

Co-administration is strictly restricted or prohibited with certain substances due to severe risk:

  • Antifolates: The combination with Trimethoprim/Sulfamethoxazole is contraindicated due to severe potentiation of the antifolate effect, leading to heightened toxicity.
  • Retinoids: Use with Acitretin is contraindicated due to the significantly increased risk of cumulative liver damage (hepatotoxicity).
  • Alcohol (Ethanol): Co-administration is strongly restricted due to the high risk of additive hepatotoxicity.
  • Live Vaccines: Contraindicated due to the risk of disseminated infection in immunosuppressed patients and decreased vaccine efficacy.

Interactions Affecting Clearance

Several medications are documented to elevate and prolong the plasma concentration of Imeth by reducing its elimination:

  • Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): These reduce the renal clearance of Imeth, leading to increased systemic exposure and potential toxicity.
  • Proton Pump Inhibitors (PPIs): These are reported to increase and/or prolong serum Imeth concentrations, particularly at high doses, by inhibiting renal elimination.
  • Penicillins: These antibiotics may increase Imeth levels by competitively inhibiting its active renal tubular secretion.

Food and Supplement Interactions

  • Food: Food intake delays absorption and reduces the peak concentration (Cmax) of orally administered Imeth.
  • Folic Acid Supplements: These supplements may reduce the medicine's therapeutic effect by antagonizing its anti-folate action, a pharmacodynamic interaction.

Mechanism of Action

Antifolate Action and Cell Proliferation Control

Imeth acts as an antifolate, a structural analog of folic acid, primarily targeting the enzyme dihydrofolate reductase (DHFR). By competitively inhibiting DHFR, the drug interrupts the synthesis of essential purine and pyrimidine nucleotides, thus halting the replication cycle of rapidly dividing cells. This results in the physiological consequence of apoptosis of specific, fast-dividing cells and inhibition of cell cycle progression.


Immunomodulation via Adenosine Signaling

The secondary, concentration-dependent mechanism is driven by internal metabolites of the drug, which indirectly lead to the accumulation and release of extracellular adenosine. This key signaling molecule activates Adenosine A2a receptors on immune cells, initiating a cascade that suppresses the production of major pro-inflammatory cytokines (e.g., IL-1, TNF-alpha). The result is a suppression of immune cell activity via receptor signaling and altered cytokine release dynamics.

Dosage and Administration Information

How Imeth is Used: Official Administration Guidelines

Imeth (Methotrexate) is administered according to a highly regulated, precise schedule that differs significantly from most other oral or injectable medications. All use must be conducted under the supervision of a specialized physician.


Administration Routes and Forms

Imeth is available for administration by several approved routes, including oral tablet or oral solution and various parenteral forms (Injection or Autoinjector) for subcutaneous (SC), intramuscular (IM), and intravenous (IV) routes. Special preservative-free formulations are required for specific routes, such as intrathecal administration.


Official Dosing and Frequency

The central instruction for the use of Imeth in chronic inflammatory conditions (like Rheumatoid Arthritis and Psoriasis) is a once-weekly schedule. This frequency must be strictly observed, with the prescribing physician specifying the exact day of intake to prevent the serious risks associated with mistaken daily use.

Condition Standard Labeled Weekly Dose Range Administration Pattern
Rheumatoid Arthritis (Adult) 7.5 mg to 20 mg once weekly Single dose or divided (e.g., 2.5 mg every 12 hours for three doses, once weekly)
Psoriasis (Adult) 10 mg to 25 mg once weekly Single dose, not ordinarily to exceed 30 mg per week

Age and Condition-Specific Rules

  • Pediatric Dosing: For conditions such as Polyarticular Juvenile Idiopathic Arthritis (pJIA), the dosage is calculated based on the child's body surface area (mg/m²) and administered once weekly.
  • Renal Impairment: Because the medicine is primarily eliminated through the kidneys, patients with impaired kidney function require dose reduction or discontinuation due to the risk of accumulation.
  • Oral Intake: Tablets may be taken with or without food.

Recent Clinical Evidence

Research evidence / Overview of studies

Overview of Efficacy Trials

Research protocols explored the drug’s observed biological activity. These trials, which were randomized and double-blind, examined endpoints related to changes in joint mobility and patient-reported stiffness.

Research Area Duration of Observation
Primary Endpoint Research protocols assessed metrics related to the frequency and severity of painful disease activity.
Study Duration Most key studies followed participants for 12 weeks to six months.

Combination Therapy Research

Research has examined protocols involving the medication used in combination with a standard conventional treatment, compared against the conventional treatment alone. Studies have evaluated research endpoints related to disease progression over extended periods.

  • Immunosuppressant Co-administration: This research focused on potential changes in biomarkers related to disease progression when the two were taken together.

Safety Profile and Tolerability Studies

Safety assessments involved monitoring for adverse events across different patient demographics.

Subgroup Focus Research Method
Renal Impairment Research protocols included participants with mild to moderate kidney impairment to evaluate adverse event rates within this subgroup.
Gastrointestinal Tolerance Research examined gastrointestinal tolerability, including a study protocol that involved administering the dose alongside food.
Early Response Indicators Early-phase studies explored the onset of measurable biomarker changes, with some protocols noting initial biomarker trends during the early phases of observation.

Frequently Asked Questions (FAQ)

Common questions about Imeth (FAQ)

Q: What is the main thing Imeth is used for?

A: According to the official product information, Imeth is approved for treating certain cancers, severe psoriasis, severe adult rheumatoid arthritis, and polyarticular juvenile idiopathic arthritis. These uses are based on the medication’s ability to act as an antifolate to control cell growth and inflammation.

Q: What is the typical timeframe before noticing an effect from Imeth?

A: Studies and official information indicate that for conditions like rheumatoid arthritis, patients may notice initial clinical improvement within 3 to 6 weeks of starting treatment. Studies suggest that further improvement may be observed over the following 12 or more weeks.

Q: How long do the effects of Imeth last after taking a dose?

A: Official pharmacokinetic data states that after taking the medication orally, the highest levels of the drug in the blood are usually reached within one to two hours. The body eliminates the drug fairly quickly, with the time it takes for half of the drug to leave the body generally ranging from 0.9 to 5.8 hours in low-dose use.

Q: Does Imeth affect sleep patterns or energy levels?

A: The official product information lists central nervous system effects such as dizziness, drowsiness, and fatigue as reported side effects. These effects may impact how a patient feels their energy levels or affects their state of wakefulness.

Q: Are the common side effects of Imeth temporary?

A: Official safety data indicates that some common effects can be transient (temporary). For example, elevations in liver enzymes, which are frequently seen when starting treatment, are usually asymptomatic and often temporary. Other acute side effects may also resolve after a few days or weeks.

Q: Does Imeth interact with common herbal supplements?

A: Regulatory documents list specific drug interactions with certain medications and supplements like folic acid. However, information regarding the safety of all herbal supplements is generally not available in the official labels. Because many herbal products are not tested for interaction with this medication, it is important to review all supplements with a healthcare provider.

Q: Is it safe to drive while taking Imeth?

A: Official warnings state that the medication may cause dizziness, fatigue, or drowsiness. Official regulatory documents caution that patients should refrain from driving or operating machinery until they understand the full impact of the medication on their physical abilities.

Q: Is Imeth considered a long-term treatment?

A: Yes, Imeth is used in the chronic management of conditions such as rheumatoid arthritis. Regulatory studies have evaluated continued therapy over two years, noting that initial clinical improvement was maintained in that timeframe.

Q: What does it mean that Imeth is 'metabolized' by the liver?

A: The term metabolism refers to how the body processes the drug. Official pharmacokinetic data shows that Imeth is partially processed by the liver into other compounds (polyglutamates), which are responsible for its effects. The drug is then eliminated from the body primarily through the kidneys.

Q: Does the effectiveness of Imeth change over time?

A: Limited long-term research indicates that for chronic conditions, the initial benefits achieved after a few months of treatment are typically maintained with continued use. Regulatory documents do not suggest a significant loss of effectiveness over time in patients who respond well to the drug.

Q: Is there a generic version of Imeth available?

A: Yes, the drug substance, methotrexate, is widely available in generic formulations. Regulatory bodies ensure that generic versions meet the same strict standards for quality and performance as the original brand-name product.

Q: Does Imeth have any known withdrawal effects if stopped suddenly?

A: While the drug does not cause typical withdrawal, regulatory documents note that when treatment is stopped, the return of the original disease symptoms may be observed within 3 to 6 weeks. This is due to the disease process resuming activity.

Q: Can Imeth cause changes in mood or personality?

A: Official safety information and patient information leaflets have reported that Imeth may be associated with mood alterations, such as mood swings or feelings of being very low (depression). Patients are advised in product labeling to report any concerning changes in mood to their prescribing doctor.

Q: Is a metallic taste in the mouth a known side effect of Imeth?

A: Official patient information indicates that a metallic taste in the mouth has been reported. This symptom may sometimes accompany other gastrointestinal side effects or be associated with more serious issues, such as kidney problems.

Q: Is Imeth a controlled substance?

A: No, Imeth (methotrexate) is not classified as a controlled substance under the U.S. Controlled Substances Act. This means its prescribing and dispensing are not subject to the same strict scheduling regulations as opioids or certain sedatives.

Q: Are there any specific lab tests needed while taking Imeth?

A: Yes, regulatory documents emphasize the need for regular patient monitoring. This typically includes periodic tests of blood counts (CBC), liver function, and renal (kidney) function before, during, and at intervals throughout therapy.

Q: What are the reported effects of Imeth on weight?

A: Some patient information related to Imeth notes that a possible side effect is loss of appetite. If a patient's appetite is reduced due to this, it may potentially lead to unintentional weight loss.

Q: Why do some people say they feel 'spacey' or 'foggy' on Imeth?

A: Official drug labels list dizziness, headache, and fatigue as common central nervous system adverse events. Patient experience may lead to subjective descriptions like 'spacey' or 'foggy' to describe these general feelings of malaise or impaired concentration.

Q: What is the difference between the brand-name Imeth and the generic formulation?

A: Regulatory guidance dictates that all generic drugs must be the bioequivalent of the brand-name product. This means the generic must contain the same active ingredient, work the same way in the body, and meet the same strict standards for quality and performance.

Q: Can Imeth cause allergic reactions, and what do they look like?

A: Yes, the medication is contraindicated in patients with a history of severe hypersensitivity, including anaphylaxis. Signs of a serious allergic reaction can include rash, hives, difficulty breathing, or swelling of the face, throat, or tongue.

Q: Is there a maximum length of time Imeth can be taken?

A: The optimal duration of therapy is not known or defined by a fixed limit. However, the official warnings state that the risk of cumulative liver damage (fibrosis and cirrhosis) is associated with prolonged use. Because of this risk, official regulatory documents mandate periodic monitoring during prolonged treatment.

Q: Is the research on Imeth mainly focused on short-term or long-term outcomes?

A: The key clinical evidence supporting the drug's use is derived from controlled studies that are typically short-to-medium term (e.g., 3 to 6 months). Regulatory documents also reference limited data from long-term extension studies that followed patients for several years.

Q: Are there specific times of day that are best for taking Imeth?

A: Official administration instructions emphasize that the medication must be taken on a strict once-weekly schedule. Regulatory documents do not specify a superior time of day (morning vs. evening), though tablets may be taken with or without food.

Q: Is Imeth known to cause problems with vision or hearing?

A: Official safety data has reported that Imeth can cause serious adverse effects, including blurred vision or sudden loss of vision. Regulatory guidance advises that any new or unusual sensory symptoms should be reported promptly to a healthcare professional.

Q: Why is Imeth prescribed less frequently for certain patients?

A: The drug is contraindicated (prohibited) or strongly warned against for use in specific patient populations, including those who are pregnant, breastfeeding, or have pre-existing conditions like severe renal impairment or chronic liver disease. These restrictions limit its use.

Q: What is the recommended approach if a minor side effect occurs with Imeth?

A: For minor, non-serious side effects (like mild nausea), common measures mentioned in patient information include resting or consuming small, bland meals. Official guidance recommends contacting a healthcare provider if side effects persist or are concerning.

Q: Does Imeth interact with common flu or COVID-19 vaccinations?

A: Official warnings state that live vaccines are generally contraindicated due to the risk of infection. For non-live vaccines (such as flu or COVID-19 shots), regulatory-aligned guidance notes that the decision to administer a vaccine and whether to temporarily interrupt therapy is a clinical decision based on the patient's status.

Q: What does the latest research say about Imeth's effectiveness?

A: Regulatory documents summarize clinical studies which found that patients treated with the drug for rheumatoid arthritis experienced improvements in joint swelling, tenderness, and overall disease activity.

How should Imeth be stored and disposed of?

Official Storage and Disposal Requirements

Methotrexate is classified by regulatory bodies as a cytotoxic (hazardous) agent, which necessitates special handling and disposal procedures to ensure safety and stability. Official storage requirements specify distinct conditions based on the product's status.

Item Requirement
Unopened Vials Store at Controlled Room Temperature (20°C to 25°C) and protect from light to maintain stability.
Opened Vials Store under refrigeration (2°C to 8°C). Must be used or discarded within 30 days of the first puncture.
Handling Due to its hazardous nature, special care must be taken to prevent skin contact or inhalation. Keep all medicine out of the reach of children and pets.
Disposal Do not dispose of in regular trash or flush down a toilet. Unwanted medicine should be taken to a DEA-authorized drug take-back site or mixed with an unappealing substance, sealed in a bag, and placed in the household trash, following local regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Imeth found in:

A-Z Index: